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Abstract
Background: Inflammatory breast cancer (IBC) is an aggressive form of BC poorly defined at the molecular level. We
compared the molecular portraits of 63 IBC and 134 non-IBC (nIBC) clinical samples.
Methodology/Findings: Genomic imbalances of 49 IBCs and 124 nIBCs were determined using high-resolution array-
comparative genomic hybridization, and mRNA expression profiles of 197 samples using whole-genome microarrays.
Genomic profiles of IBCs were as heterogeneous as those of nIBCs, and globally relatively close. However, IBCs showed more
frequent ‘‘complex’’ patterns and a higher percentage of genes with CNAs per sample. The number of altered regions was
similar in both types, although some regions were altered more frequently and/or with higher amplitude in IBCs. Many
genes were similarly altered in both types; however, more genes displayed recurrent amplifications in IBCs. The percentage
of genes whose mRNA expression correlated with CNAs was similar in both types for the gained genes, but ,7-fold lower in
IBCs for the lost genes. Integrated analysis identified 24 potential candidate IBC-specific genes. Their combined expression
accurately distinguished IBCs and nIBCS in an independent validation set, and retained an independent prognostic value in
a series of 1,781 nIBCs, reinforcing the hypothesis for a link with IBC aggressiveness. Consistent with the hyperproliferative
and invasive phenotype of IBC these genes are notably involved in protein translation, cell cycle, RNA processing and
transcription, metabolism, and cell migration.
Conclusions: Our results suggest a higher genomic instability of IBC. We established the first repertory of DNA copy number
alterations in this tumor, and provided a list of genes that may contribute to its aggressiveness and represent novel
therapeutic targets.
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Introduction
Inflammatory breast cancer (IBC) [1] is one of the most lethal
forms of breast cancer because of its high metastatic potential [2].
IBC is classified T4d in the TNM-UICC classification. Diagnosis
is based on clinical signs: edema, erythema, pain, breast widening,
and induration [2]. Most cases are associated with a ductal type
and a high histological grade [3]. The presence of tumor emboli in
dermal lymphatics, although not mandatory for the diagnosis, is a
pathological hallmark of 50–75% of IBCs, Emboli are non-
adherent cell clusters that rapidly spread by continuous passive
dissemination [4], thus favoring both distant metastasis and local
recurrence. Despite progresses due to the multi-modality treat-
ment [2,5], the prognosis remains poor with a 3-year survival of
,50% [6]. New molecular therapeutic targets need to be
identified to improve treatment and increase patient survival.
Molecular mechanisms underlying IBC are poorly known (for
review, see [7,8]). IBCs are more frequently estrogen receptor (ER)
and progesterone receptor (PR) negative, ERBB2 and EGFR
positive. They frequently present P53 alterations and WISP3 loss-
of-expression [9–15]. They show high angiogenic and angioinva-
sive capacities and express high levels of angiogenic factors [16].
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[18,21,22], and NF-kB pathway-related proteins [23,24]. Recent-
ly, a role for eIF4G1 has been suggested in the formation of tumor
emboli, pointing to the importance of translation control in IBC
[25].
High-throughput molecular approaches have led to important
insights in the molecular heterogeneity of non-IBC (nIBC), notably
by identifying biologically and clinically relevant subtypes (luminal
A and B, basal, ERBB2-overexpressing, normal-like) [26]. More
recently, IBCs have been studied at the mRNA level using DNA
microarrays [27–33]. The results showed the presence of the five
molecular subtypes in IBCs, and the definition of IBC versus nIBC
gene expression signatures. But the studied series remain relatively
small, with 35 IBC samples in the largest one [27,28]. DNA copy
number alterations (CNAs) may account for phenotypic and
expression differences between IBCs and nIBCs. However, in
contrast to nIBCs [34–39], genomic imbalances have not yet been
analyzed in IBC by using recent techniques such as array-
comparative genomic hybridization (aCGH) or SNP-arrays. The
rare genomic studies performed to date used low resolution
methods [40–42]. Similarly, whole-genome integrated studies
(associating analysis of DNA CNAs and mRNA expression levels)
have been done in nIBC [34,39,43,44], but never in IBC. Such
approaches provide opportunities to better elucidate IBC at the
DNA and RNA levels.
Here, we have studied and compared DNA CNAs and mRNA
expression deregulation on a whole-genome scale in a large series
of IBCs and nIBCs. To our knowledge, this is both the first high-
throughput aCGH analysis of IBC and the first whole-genome
integrated analysis comparing IBC vs nIBC. This is also the largest
series of IBC profiled using high-throughput molecular analyses.
Materials and Methods
Breast cancer samples and histoclinical characteristics
Pre-treatment tumor tissues were collected from 197 patients
with invasive adenocarcinomas, who underwent surgical biopsies
or initial surgery at the Institut Paoli-Calmettes (IPC, Marseille,
France) between 1987 and 2007. Each patient gave written
informed consent and the study was approved by the IPC ‘‘Comite ´
d’Orientation Strate ´gique’’. Tumor samples were macrodissected
and frozen in liquid nitrogen within 30 minutes of removal. Before
RNA extraction, tumor sections were reviewed by two pathologists
(ECJ and JJ) and contained more than 60% of tumor cells. The
197 samples comprised 63 IBCs and 134 nIBCs. IBC tumors were
selected upon clinical criteria as T4d tumor. The control group
(nIBCs) represented a mixture of early (121 samples, including 68
with pathological axillary lymph node involvement).and locally-
advanced stages (13 samples), as found in previous studies [27–
29,32,33]. Using only locally-advanced cases as controls would
introduce a bias toward the discovery of molecular differences
related to the difference of growth kinetics between IBCs (sudden
onset and rapid growth) and nIBCs (long-standing evolution with
slower growth). Immunohistochemistry (IHC) status was available
on most samples for ER (positivity cut-off: 10%), ERBB2 (0–3+
score, DAKO HercepTest, with .1+ defined as positive), and P53
(positivity cut-off: 1%). Patients were treated according to standard
guidelines. The main histoclinical characteristics are listed in
Table 1. As expected, IBCs were associated with more unfavorable
prognostic features and poorer survival than nIBCs.
DNA and RNA extraction
DNA and RNA were extracted from frozen samples by using
guanidium isothiocynanate and cesium chloride gradient. DNA
and RNA quality was respectively controlled on polyacrylamide
gel electrophoresis and on Agilent Bioanalyzer (Agilent Technol-
ogies, Massy, France).
Array-comparative genomic hybridization profiling and
data analysis
From the 197 samples analyzed, DNA was available for 173,
including 49 IBCs and 124 nIBCs. Genomic imbalances of the
DNA samples were determined by using high-resolution 244K
CGH microarrays (Hu-244A, Agilent Technologies, Massy,
France). A pool of 13 normal male DNA was used as reference.
Scanning was done with Agilent Autofocus Dynamic Scanner
(G2565BA, Agilent Technologies). Data analysis was done and
Table 1. Histoclinical characteristics of the 197 breast cancer
samples.
Characteristics (N) IBC nIBC p
N=63 (%) N=134 (%)
Median age, years (range) (197) 48 (24–82) 56 (28–84) 1.26E-03
Pathological tumor size, pT (133)
pT1 NA 31 (23%)
pT2 NA 70 (53%)
pT3 NA 32 (24%)
Pathological axillary lymph node
status, pN (133)
negative NA 57 (43%)
positive NA 76 (57%)
Grade (190) 1.35E-12
1 0 (0%) 32 (24%)
2 10 (17%) 62 (47%)
3 48 (83%) 38 (29%)
IHC ER status (197) 7.74E-03
negative 33 (52%) 43 (32%)
positive 30 (48%) 91 (68%)
IHC ERBB2 status (171) 2.16E-04
negative 30 (61%) 107 (88%)
positive 19 (39%) 15 (12%)
IHC P53 status (163) 5.82E-04
negative 15 (35%) 79 (66%)
positive 28 (65%) 41 (34%)
Molecular subtype (197) 5.08E-05
basal 13 (21%) 25 (19%)
ERBB2 13 (21%) 10 (7%)
luminal A 9 (14%) 63 (47%)
luminal B 15 (24%) 18 (13%)
normal 13 (21%) 18 (13%)
Genomic pattern (173) 9.30E-04
complex sawtooth 16 (33%) 23 (19%)
complex firestorm 27 (55%) 52 (42%)
simplex 6 (12%) 49 (40%)
5-year MFS (191) 37% 80% 4.40E-10
5-year OS (181) 57% 84% 5.50E-11
NA, not assessable
doi:10.1371/journal.pone.0016950.t001
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gies). Extraction of data (log2 ratio) was done from CGH analytics,
while normalized and filtered log2 ratio were obtained from
‘‘Feature extraction’’ software (Agilent Technologies). Data
generated by probes mapped to X and Y chromosomes were
eliminated. The final dataset contained 225,388 unique probes
covering 22,509 genes and intergenic regions according to the
hg17/NCBI human genome mapping database (build 35). Data
were analyzed using circular binary segmentation (CBS) as
implemented in the DNA copy R/Bioconductor package [45]
with default parameters to translate intensity measurements in
regions of equal copy number, each region being defined by at
least five consecutive probes. Thus, each probe was assigned a
segment value referred to as its ‘‘smoothed’’ value.
We used two different threshold values (log2 ratio .|0.5|, and
|1|) to distinguish low level from high level CNAs [43]. DNA copy
number patterns were classified as ‘‘simplex’’ (very few CNAs),
‘‘complex sawtooth’’ (many low-level CNAs), or ‘‘complex
firestorm’’ (low-level CNAs and recurrent amplifications) [46,47].
Unsupervised analysis was done with the Cluster program [48]
using log2 ratio data, complete linkage and Pearson correlation as
similarity metrics. Results were displayed using TreeView [48]. To
determine the robustness of the resulting tumor clusters, we used R
package Pvclust [49] with multiscale bootstrap resampling using
1,000 iterations. Approximately Unbiased (AU) p-values $90%
were used to define the significant clusters. To identify altered
regions, we used the GISTIC algorithm [50], which computes for
each segment through the genome a score based on the frequency
of CNA combined with its amplitude, with bootstrapping to
calculate the significance level (p,0.05). To identify genes with
different CNA frequencies between IBCs and nIBCs, the
frequency of CNAs was computed for each probe locus as the
proportion of samples showing an aberration therein. Alteration
frequencies were compared using the Fisher’s exact test and false
discovery rate (FDR) was applied to correct the multiple testing
hypothesis (p,0.05) [51].
Gene expression profiling and data analysis
Gene expression data of the 197 BCs and 4 normal breast (NB)
samples, which represented 1 pool of 4 samples from 4 women,
and 3 commercial pools of respectively 1, 2 and 4 normal breast
RNA (Clontech, Palo Alto, CA), were quantified using whole-
genome DNA microarrays (HG-U133 Plus 2.0, Affymetrix).
Scanning was done with Affymetrix GeneArray scanner and
quantification with Affymetrix GCOS software. Data were
analyzed by the Robust Multichip Average method in R using
Bioconductor and associated packages [52]. Robust Multichip
Average did background adjustment, quantile normalization, and
summarization of 11 oligonucleotides per gene. Before analysis, a
first filtering step removed from the dataset the genes with low and
poorly measured expression as defined by an expression value
inferior to 100 units in all samples. All data was then log2-
transformed for display and analysis.
Before clustering analysis, a second filtering retained the 12,813
probe sets with the most variable expression across all samples.
Clustering was done with the Cluster program [48] using Pearson
correlation as similarity metrics and centroid linkage clustering.
Results were displayed using TreeView program [48]. The
molecular subtypes of breast cancer were determined using the
single sample predictor (SSP) classifier based on the list of 306
intrinsic genes as described [53]. The sample was attributed the
subtype corresponding to the most correlated centroid. To develop
a predictive model based on the expression of the 24 genes
identified by integrated analysis (see below), we applied a logistic
regression analysis using the glm function in R statistical package.
Once defined, the model was applied to expression data to assign
the ‘‘IBC-like’’ or the ‘‘nIBC-like’’ class: first for testing its
robustness by leave-one-out cross-validation [54] in the learning
set and by validation in an independent set of 24 IBC and nIBC
samples, then for estimating its prognostic value in public nIBC
datasets.
Genomic and expression data are MIAME-compliant (http://
www.mged.org/Workgroups/MIAME/miame.html) and the raw
data have been deposited in the MIAME-compliant GEO
database (GSE23720).
Integrated analyses of genome and expression data
Before integrated analysis, Affymetrix expression probe sets
were matched with Agilent aCGH probes using the hg17/NCBI
database. When multiple Affymetrix probe sets mapped to the
same gene, the probe sets with an extension « _at », next « s_at »,
and followed by all other extensions were preferentially kept.
When several probe sets with the best extension were available, the
one with the highest median value was retained.
We analyzed the degree of correlation between RNA expression
and CNAs for the genes and tumors (173 tumors) profiled with
both platforms. For each gene with a CNA in at least two IBCs or
nIBCs, a Student t-test compared the expression levels in samples
with and without the corresponding CNA (FDR-corrected
p,0.05). Comparative integrated analysis of IBCs and nIBCs
was only applied to the genes with CNA frequencies significantly
different between IBCs and nIBCs (628 genes). Genes had to
satisfy three other criteria: i) frequencies of combined alterations
(gain associated with overexpression vs other combinations, and
conversely, loss associated with underexpression vs other combi-
nations) different (Fisher exact test) between IBCs and nIBCs, ii)
correlation (Student t-test) between CNA and expression in the
173 samples, and iii) expression different (Student t-test) between
IBCs and nIBCs. In the first above-quoted step, overexpression
and underexpression for a given gene were assigned using a
threshold of |1| corresponding to twice the expression level
found in the normal breast pool. These steps are summarized in
Figure S1.
Public gene expression data of breast cancer
To test the prognostic performance of our 24-gene signature in
nIBCs, we analyzed 6 public data sets collected from five
publications [55–59], and from the UNC Microarray Database
(Table S1). When different publications included the same patients
redundancy was eliminated, resulting in 1,781 different patient
samples available for analysis. Before analysis, we mapped
hybridization probes for the 24 genes across the two oligonucle-
otide-based platforms used across the series. When multiple probes
were mapped to the same GeneID (EntrezGene identification
number), the one with the highest variance in a particular dataset
was selected to represent the GeneID. Analysis of each data set
(using available normalized data) was done separately to guarantee
a larger number of genes common with our signature.
Statistical analysis
Correlations between sample groups and histoclinical factors
were calculated with the Fisher’s exact test for qualitative variables
with discrete categories, and the Mann-Whitney test for
continuous variables. Follow-up was measured from the date of
diagnosis to the date of last news for patients without any event.
Disease-free survival (DFS) was calculated from the date of
diagnosis until the date of first relapse whatever its location (local,
regional or distant) or date of death (when the relapse data was not
Genomics of Inflammatory Breast Cancer
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pared between groups with the log-rank test. Univariate and
multivariate analyses were done using Cox regression analysis.
The p-values were based on the Wald test, and patients with one
or more missing data were excluded. All statistical tests were two-
sided at the 5% level of significance. Analyses were done using the
survival package (version 2.30), in the R software (version 2.9.1).
Results
Genome and transcriptome analysis of breast cancer
We first describe the results on the whole set of tumors before
addressing the specific question of IBC. High-resolution aCGH
was performed on 173 samples, including 49 IBCs and 124 nIBCs.
Figure 1A (left) shows the frequency of low level CNAs in all
samples. As previously reported [37,44], the three most frequently
gained regions were on 1q, 8q and 17q chromosomal arms,
whereas the regions frequently lost were on 8p, 11q and 16q. The
median percentage of probe sets displaying a CNA in a sample was
3.5%, with a great variability between samples (range, 0.03–44%).
As expected, this percentage was higher in grade 3 tumors (2.1%)
than in grade 1 tumors (0.5%; p=0.005; Mann-Whitney test).
To display the similarity of samples with respect to their genome
profiles, unsupervised hierarchical clustering was applied to aCGH
data of all 173 samples and all 225,388 oligonucleotide probes
(excluding X and Y probes) (Figure 1B). Pvclust algorithm
identified three robust tumor clusters, which correlated with the
molecular subtypes of samples, and other histoclinical features
(Table S2). No correlation existed with the IBC/nIBC status,
suggesting similar whole-genome genomic profiles in IBCs and
nIBCs, and a similar heterogeneity. Using a previous classification
of genome profiles [39,47], 55 cases (32%) were ‘‘simplex’’, 39
(23%) ‘‘complex sawtooth’’, and 79 (45%) ‘‘complex firestorm’’.
This status correlated with the grade of tumors. Only 13% of
grade 3 tumors were ‘‘simplex’’, whereas 87% were ‘‘complex’’.
Conversely, 61% of grade 1 tumors were ‘‘simplex’’ and 38%
‘‘complex’’.
The 173 samples and 24 additional samples (197 including 63
IBCs and 134 nIBCs) were profiled using whole-genome mRNA
expression microarrays. Figure S2 shows the hierarchical cluster-
ing of samples based on the expression of 12,813 probe sets.
Samples were sorted into three major clusters, which strongly
correlated with histoclinical features (grade, IHC data) and
molecular subtypes, but not with the IBC status. As with aCGH
Figure 1. aCGH portrait of breast cancers. A) Frequency plots of genome CNA. Frequencies (horizontal axis, from 0 to 100%) are plotted as a
function of chromosome location (from 1pter to the top, to 22qter to the bottom), for all breast cancer samples (Global, N=173), for IBCs (N=49),
and for nIBCs (N=124). Horizontal lines indicate chromosome boundaries. Positive and negative values indicate frequencies of tumors showing copy
number increase and decrease, respectively, with gains (in red) and losses (in green). B) Unsupervised hierarchical clustering of genome CNAs
measured for 173 breast cancers on 225,388 probes (without X and Y). Red indicates increased DNA copy number gain and green indicates decreased
copy number. The bars to the left indicate chromosome locations ordered like in A). The vertical orange lines define the three significant tumor
clusters (I, II and III). Above the dendrogram, p indicates the Approximately Unbiased (AU) p-values defined by Pvclust. Below the dendrogram, the
row indicates the clinical type (green for nIBC, and orange for IBC).
doi:10.1371/journal.pone.0016950.g001
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differences due to clinical type. IBCs were scattered across the
three clusters, intermixed with nIBCs, suggesting that, at the RNA
level and on a whole-genome scale, they are as heterogeneous
as nIBCs.
Regions and genes with significant genome aberrations
in IBCs
Our first objective was to establish the first repertoire of genome
CNAs in IBC. Table S3 shows the regions with frequent low and/
or high level CNAs in the 49 IBCs, defined using the GISTIC
algorithm with a significance threshold of p,0.05. Sixty-five
regions were gained/amplified. The top ten regions (in term of
median GISTIC score) resided on 17q, 6p, 1q, 8q, 11q, 19q, and
8p chromosomal arms. Many of these regions contain genes
involved in breast cancer, such as ERBB2, MYC, CCND1 and
FGFR1. Thirty-four regions were gained in at least 15% of IBCs.
The most frequently gained region (.40%) was 8q12.1–24.3,
and contained 461 genes. A total of 216 regions were lost/deleted,
with the top ten (in term of median GISTIC score) distributed in
4q, 3q, 1q, 9q, 15q and 2q. Only 4 regions were lost in at least
15% of IBCs.
At the gene level, 321 genes were amplified in at least 10% of
IBCs (Table S4). As expected, all were located in the 65 regions
gained/amplified reported above. They included validated or
potential therapeutic targets such as ANGPT1, ERBB2, FGFR1,
GRB7, MYC, PAK1, PNMT, PROSC, SQLE, and STK3. Other
targets such as ADAM9 (6% of cases), EGFR, FNTA, and IKBKB
(4%), AKT3, AREG, BRAF, EREG, FYN, and RET (2%) were less
frequently amplified, but sometimes at a very high level (log2 ratio
.|1|). The 15 genes that were the most frequently amplified are
located in 17q12 and 8q24 (Table 2). Additionally, rare high-level
amplifications targeted other potential therapeutic targets such as
DCK, FGF3, FGF10, FLI1, IL6, MFHAS1, ROS1 and SRC.
Conversely, 21 genes were deleted in at least 10% of IBCs
Table 2. Top 15 genes with high level CNAs in at least 10% of IBCs.
Symbol Name Cytoband
Amplification frequency
in IBCs
PNMT phenylethanolamine N-methyltransferase 17q12 29%
PERLD1 per1-like domain containing 1 17q12 29%
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 17q12 29%
C17orf37 chromosome 17 open reading frame 37 17q12 29%
CASC3 cancer susceptibility candidate 3 17q21.1 29%
STARD3 StAR-related lipid transfer (START) domain containing 3 17q12 27%
TCAP titin-cap (telethonin) 17q12 27%
GRB7 growth factor receptor-bound protein 7 17q12 27%
C8ORFK23 Transcribed locus 8q24.13 24%
C8orf54 chromosome 8 open reading frame 54 8q24.13 24%
PVT1 Pvt1 oncogene homolog, MYC activator (mouse) 8q24.21 24%
BC009730 Homo sapiens, clone IMAGE:3884408, mRNA 8q24.21 24%
EIF3H eukaryotic translation initiation factor 3, subunit H 8q24.11 24%
EXT1 exostoses (multiple) 1 8q24.11 24%
SAMD12 sterile alpha motif domain containing 12 8q24.12 24%
Symbol Name Cytoband
Deletion frequency in
IBCs
ADAM3A ADAM metallopeptidase domain 3A (cyritestin 1) 8p11.23 22%
C14orf80 chromosome 14 open reading frame 80 14q32.33 22%
ADAM5P ADAM metallopeptidase domain 5 pseudogene 8p11.23 20%
CRIP1 cysteine-rich protein 1 (intestinal) 14q32.33 20%
UGT2B17 UDP glucuronosyltransferase 2 family, polypeptide B17 4q13.2 16%
U06641 4q13.2 16%
TMPRSS11E transmembrane protease, serine 11E 4q13.2 16%
THOC4 THO complex 4 17q25.3 16%
LOC92659 hypothetical protein BC009233 17q25.3 16%
NOTUM notum pectinacetylesterase homolog (Drosophila) 17q25.3 16%
DEFB107A defensin, beta 107A 8p23.1 14%
DEFB104A defensin, beta 104A 8p23.1 14%
DEFB4 defensin, beta 4 8p23.1 14%
GSTT1 glutathione S-transferase theta 1 22q11.23 14%
RAB40C RAB40C, member RAS oncogene family 16p13.3 14%
doi:10.1371/journal.pone.0016950.t002
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regions.
Comparative genome analysis of IBCs and nIBCs
We compared the genomic profiles of 173 samples (49 IBCs and
124 nIBCs). Globally, as shown in Figure 1A, IBCs looked like
nIBCs, since both phenotypes showed similar altered regions with
similar frequencies of alterations for most of them. However, some
differences were visually apparent, such as the more frequent gain
of 1q, 8q and 17q regions in IBCs, or the more frequent loss of 4p,
8p, 11q, and 16q regions in nIBCs. The median percentage of
probe sets displaying a CNA for a sample was higher in IBCs
(3.7%, range 0.01–14%) than in nIBCs (1.9%, range 0.01–26%;
p=6.1.E–253, Fisher’s exact test), even if a great variability
between samples existed for both types. IBCs showed a higher
proportion of ‘‘complex sawtooth’’ and ‘‘complex firestorm’’
profiles than nIBCs, which conversely showed a higher proportion
of ‘‘simplex’’ profiles (p=0.0009, Fisher’s exact test) (Figure S3).
The comparative analysis of regions with frequent low and/or
high level CNA in IBCs vs nIBCs showed very similar results in
term of number of altered regions (71 and 77 gained respectively,
and 210 lost in both types) (Table S5). Many altered regions were
similar. Some of them, such as 4q13.2 and 11q11, were similarly
altered (similar GISTIC scores) whereas others, such as 1q21.2–
q41, 8p11.21–p12, 8q11.1–q24.3, 11q13.33–q14.1, 17q11.1–
q21.2, and 20q13.2–q13.33 were differentially altered (different
GISTIC scores) either because of a higher frequency and/or
higher amplitude of alteration. Other regions were specifically
altered, such as 5p15.33 in IBCs or 3q26.1 in nIBCs.
The number of genes amplified or deleted was higher in IBCs
than in nIBCs (Table S4). Only 26 genes were amplified in at least
10% of nIBCs, vs 321 in IBCs. As expected, these genes are
located within amplicons classically described in breast cancer on
8p, 11q and 17q. Sixteen genes (vs 21 in IBCs) were deleted in at
least 10% of nIBCs. Supervised analysis identified 9,148 probes,
representing 628 unique sequences/genes, with different CNA
frequency in IBCs and nIBCs (Tables S6A–B). A total of 514 genes
displayed gains and/or amplifications differentially associated with
IBCs vs nIBCs, including 484 genes gained/amplified more
frequently in IBCs, and only 30 gained more frequently in nIBCs
(Table S6). Compared to nIBCs, IBCs were associated with the
gain of 382 genes scattered through 13 chromosomal arms (1p, 4q,
5p, 6p, 6q, 7p, 8q, 10q, 12q, 14q, 17q, 19p, and 20q). Figure S4
shows an example of genomic profiles for the 6q21 region. The
frequently gained 8q21.2–24.3 region included more than 230
gained genes, including MTDH (8q22.1), RRM2B, AZIN1, FZD6
(8q22.3), ANGPT1, EIF3E (8q23.1), DCC1, MTBP (8q24.12) and
ATAD2, SQLE (8q24.13). By contrast, only 30 genes, scattered
through two chromosomal arms (3q and 16p), were more
specifically gained in nIBCs, including MYH11, C16orf63
(16p13.11), ERCC4 (16p13.12), and A2BP1 (16p13.3). Thus,
specific gains were more frequently observed in IBCs than in
nIBCs. The mean frequency of tumors displaying a gain for one
gene of these respective lists was 31% for IBCs (maximum 53% for
genes located in the 8q22.3–24.11 region), and only 9% for nIBCs
(maximum 10% for genes located in the 16p13.11 region). A total
of 189 genes were more frequently amplified in IBCs than in
nIBCs. Most of them were located within five chromosomal arms
(1q, 8p, 8q, 17q, and 18p). Several genes such as RAD21 (8q24.11),
MTBP (8q24.12), MYC, PVT1 (8q24.21), ERBB2 (17q12), and
CASC3 (17q21.1) are known cancer-related genes. Ninety-nine of
these 189 genes were amplified in at least 10% of IBCs. The mean
frequency of IBCs with amplification for one of these genes was
14% (maximum 29% for genes such as ERBB2 located in the
17q12 region). In contrast, no gene was more frequently amplified
in nIBCs than in IBCs.
A total of 114 genes displayed genomic losses and/or deletions
differentially associated with IBCs vs nIBCs, including 68 genes
lost/deleted more frequently in IBCs, and 46 more frequently in
nIBCs (Table S7). Fifty-nine genes were more specifically lost in
IBCs, affecting 7 chromosomal arms (4p, 5q, 6q, 12p, 15q, 19q,
and 22q). Examples include EMB (5q11.1), RPS5, UBE2M
(19q13.43), SLIT2 (4p15.31) and EZR (6q25.3). Conversely, 46
genes were more specifically lost in nIBCs, affecting two
chromosomal arms (8p, and 16q). Examples include PKD1L2
(16q23.2), FOXC2 and FOXF1 (16q24.1). Loss and amplification of
BC028701, FKSG2 and KCNU1 (8p12), were correlated with nIBCs
and IBCs, respectively. The mean frequency of tumors displaying
a loss for one gene of these respective lists was 11% for IBCs
(maximum 24% for genes located in the 6q27 and 22q13.1
regions), and 20% for nIBCs (maximum 21% for genes located in
the 16q24.1 region). In IBCs homozygous deletions (no copies
assuming a modal diploid genome) targeted 9 genes located on five
chromosomal arms (3q, 8p, 13q, 14q, and 18q). Four of them were
deleted in at least 10% of IBCs. The mean frequency of IBCs with
deletion for one of these genes was 10% (maximum 14% for genes
located in the 8p23.1 region). No homozygous deletion was more
frequently found in nIBCs.
Thus, among the 628 genes (514 gained/amplified and 114
lost/deleted) with CNAs differentially represented between IBCs
and nIBCs, 552 (484 and 68; 88%) were associated with IBCs and
76 (30 and 46; 12%) with nIBCs.
Correlations between gene expression and CNA
We compared the degree of CNA-driven mRNA up and
downregulation in 49 IBCs and 124 nIBCs profiled on both
platforms by analyzing the 13,127 genes common to the two
platforms and retained after filtering based on the expression
levels.
In IBCs, from all genes with a CNA (gains/amplifications and
losses/deletions) in at least two samples, 10.4% of gained genes
exhibited mRNA expression correlated with the gain, and 1.5% of
lost genes exhibited expression correlated with the loss (Table S8).
In nIBCs, these respective features were 10.4% and 9.5%. For the
gained genes, the percentages of correlations were similar in IBCs
and nIBCS but for the lost genes, this percentage was 7-fold more
important in nIBCs than in IBCs (p,1.E-12, Fisher’s exact test;
OR=0.14 (CI95% 0.09–0.20)).
Integrated comparative analysis and IBC-specific
candidate genes
To identify potential IBC-specific candidate genes, we com-
pared in the 173 IBCs and nIBCs only the genes with deregulated
mRNA expression in relation to CNA (Figure S1).
Out of the 628 genes identified by supervised analysis with CNA
frequencies different between IBCs and nIBCs, 500 were present
on the Affymetrix microarrays. They were represented by 748
probe sets on these microarrays, and 4,259 probes on the Agilent
microarrays. From these 500 genes, we identified 24 genes whose
expression was deregulated in relation to CNA with significant
differences between IBCs and nIBCs (Table 3; Table S9; Figure 2).
In all cases, the transcriptional deregulation was associated with
IBCs only and corresponded to an overexpression related to a gain
(21 genes) and/or amplification (13 genes). By definition, these 24
genes were also overexpressed in IBCs as compared to nIBCs.
Twenty of these genes are located in 8q22–q24 and 17q21,
including PAPBC1, RAD21, ATAD2, MTSS1, SQLE, ST3GAL1,
C17orf37, ABCC3 and PTPN2, previously reported as cancer-
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downregulated and loss-targeted in IBCs.
To validate the association of these 24 genes with the IBC/
nIBC distinction, we analyzed the 24 remaining breast tumors (14
IBCs and 10 nIBCs) only profiled on our Affymetrix platform.
None of them had been included in the 173 tumors from which
the 24 gene-list had been derived. First, we defined an IBC/nIBC
genomic classifier by applying logistic regression to the expression
data of the 24 genes in the 173 samples (learning set). As expected,
the rate of accurate resulting classification was high (86%). Leave-
one-out cross-validation gave similar results with a rate of 82%
(p=2.94E-11, Fisher’s exact test; Figure 3A). Then, we applied the
predictor to our validation set of 24 samples (Figure 3B): 75% of
samples (10/14 IBCs and 8/10 nIBCs; p=0.03, Fisher’s exact test)
were correctly classified, suggesting the robustness of the classifier.
Because of the differences between IBC and nIBC regarding
some histoclinical features such as grade, ER, ERBB2 and P53
status, we verified that our 24-gene signature was more associated
to the IBC/nIBC distinction than to any of these features. This
was done by comparing the p-values testing the correlations
between the ‘‘IBC-like’’/‘‘nIBC-like’’ classes and each feature
(Figure 3A–B). This was further confirmed by regression analysis
on the whole set of samples testing and comparing the ability of
each variable (24-gene signature, grade, ER, ERBB2 and P53
status) to discriminate IBC from nIBC (Table 4). Three features
were significant in univariate analysis (24-gene signature, ERBB2
and P53 status), and two, including the 24-gene signature,
remained significant in multivariate analysis. Altogether, these
data indicated that our 24-gene signature is more linked to the
distinction IBC/niBC than to other potential confounding
variables.
Prognostic value of the 24-gene signature
Given the poor prognosis of IBCs, we hypothesized that the 24-
gene predictor, if biologically relevant with respect to the IBC/
nIBC distinction, might be prognostic in breast cancer. We thus
tested its prognostic value in a series of 1,781 clinically annotated
nIBCs. Using our 24-gene model (the number of genes common
with each data set ranged from 17 to 24), we attributed to each
sample an ‘‘IBC-like’’ or ‘‘nIBC-like’’ profile. All series were then
pooled, resulting in 338 nIBCs with an ‘‘IBC-like’’ profile and
1,323 with a ‘‘nIBC-like’’ profile (Figure 3C).
We compared the DFS of these two nIBC classes for the 1,420
patients with available clinical outcome. With a median follow-up
of 91 months after diagnosis (range, 1 to 220), the ‘‘nIBC-like’’
class had a 5-year DFS of 73%, better than the survival of the
‘‘IBC-like’’ class with a 5-year DFS of 61% (p=4.4.E-4, log-rank
test). Survival curves are shown in Figure 3D.
We then performed univariate and multivariate DFS analyses
(Table 5). In addition to the ‘‘IBC-like’’ or ‘‘nIBC-like’’ profile, we
tested the variables most frequently annotated in the six data sets:
patients’ age, pathological tumor size, axillary lymph node status,
and grade, and IHC ER and PR status (ERBB2 status not
available). All features, except age and PR status, were significant
Table 3. List of 24 candidate genes with gain or amplification correlated with overexpression showing significant frequency
differences between IBCs and nIBCs.
Symbol Name Cytoband
RBM13 RNA binding motif protein 13 8p12
RAD54B RAD54 homolog B (S. cerevisiae) 8q22.1
KIAA1429 KIAA1429 8q22.1
INTS8 integrator complex subunit 8 8q22.1
VPS13B vacuolar protein sorting 13 homolog B (yeast) 8q22.2
PABPC1 poly(A) binding protein, cytoplasmic 1 8q22.3
C8orf53/UTP23 chromosome 8 open reading frame 53 8q24.11
RAD21 RAD21 homolog (S. pombe) 8q24.11
TAF2 TAF2 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 150 kDa 8q24.12
DCC1 defective in sister chromatid cohesion homolog 1 (S. cerevisiae) 8q24.12
MTBP Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) binding protein, 104kDa 8q24.12
WDR67 WD repeat domain 67 8q24.13
ATAD2 ATPase family, AAA domain containing 2 8q24.13
MTSS1 CDNA FLJ12372 fis, clone MAMMA1002446 8q24.13
SQLE squalene epoxidase 8q24.13
ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 8q24.22
ARID2 AT rich interactive domain 2 (ARID, RFX-like) 12q12
C17orf37 chromosome 17 open reading frame 37 17q12
MRPL27 mitochondrial ribosomal protein L27 17q21.33
LRRC59 leucine rich repeat containing 59 17q21.33
EPN3 epsin 3 17q21.33
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 17q21.33
INTS2 integrator complex subunit 2 17q23.2
PTPN2 protein tyrosine phosphatase, non-receptor type 2 18p11.21
doi:10.1371/journal.pone.0016950.t003
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for ‘‘IBC-like’’ tumors compared to ‘‘nIBC-like’’ tumors ([95%CI
1.17–1.73], p=4.7.E-4). In multivariate analysis, these five
variables, including the 24-gene model-based classification,
retained significant prognostic value, suggesting that our IBC
signature is an independent prognostic feature in nIBC, with a HR
for relapse for ‘‘IBC-like’’ tumors vs ‘‘nIBC-like’’ tumors equal to
1.34 ([95%CI 1.06–1.70], p=0.015). This observation confirmed
that the 24-gene signature contained some prognostic information,
which might explain the worse prognosis of IBCs.
Discussion
We applied high-throughput molecular analyses to a large series
of IBCs and nIBCs. Because copy-number changes drive a
considerable proportion of the transcriptional changes [34], we
compared genome copy number and expression profiles to iden-
tify potential IBC-specific candidate genes. To our knowledge,
this is the first high-resolution aCGH study of IBC, the first
integrated genomic analysis for IBC vs nIBC comparison, and the
largest series of IBCs profiled using high-resolution genomic
analytic tools.
Genomic alterations in IBC
Because of the high number of CNAs observed in breast cancer,
we used stringent log2 ratio threshold values to define the most
specific genomic aberrations. We did not separate IBCs from
nIBCs on the basis of whole genome profiles, which were globally
very close, suggesting that IBCs are as heterogeneous as nIBCs at
the genome level and that different obvious genome alterations are
not what distinguish them. However, the number and frequency of
CNAs were more important in IBCs than in nIBCs, as well as the
proportion of ‘‘complex sawtooth’’ and ‘‘complex firestorm’’
profiles, clearly suggesting that the genomic differences between
them are not due to a possible damping of the nIBC signal by
higher contamination with normal tissue. Among the 628 genes
with CNAs differentially represented between IBCs and nIBCs,
88% were associated with IBCs and only 12% with nIBCs. These
results indicate a higher degree of genomic instability in IBCs, in
agreement with their high grade, frequency of P53 mutations and
their aggressiveness. Given this genomic complexity and hetero-
geneity of IBCs, and the low degree of differences observed with
nIBCs globally, future studies should ideally compare IBCs and
nIBCs within molecular subgroups defined by expression (molec-
ular subtypes) and/or by CNA (simplex, complex sawtooth,
Figure 2. Chromosomal location of the IBC candidate oncogenes. The 24 candidate oncogenes defined by comparative integrated analysis
are shown associated with their corresponding chromosome CNA frequency plot in 49 IBCs and 124 nIBCs. A threshold value of log2 ratio .|0.5| was
used to draw chromosome CNA frequency plots using CGH AnalyticsH software.
doi:10.1371/journal.pone.0016950.g002
Genomics of Inflammatory Breast Cancer
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e16950complex firestorm) profiles as recently suggested [60]. In this
context, and given the scarcity of IBC, international collaborations
are underway for collecting enough IBC samples that should allow
identifying genomic alterations perhaps more specific of IBC.
However, even if the number of profiled samples is relatively
small, our series represents the largest tumor set reported in
literature, and its study provides several interesting results. We
identified 65 regions with gain/amplification and 216 with loss/
deletion in IBCs. Few data are available in literature regarding the
genomic imbalances in IBCs [40–42], and none has been done
using high-resolution aCGH. A study of loss of heterozygosity at 71
microsatellite markers in 66 IBCs [41] reported deletions of various
chromosomal regions including 3p14–p21.2, 6p, 8p22, 11q22–q23,
11q24–q25, 13q14, and especially 17q21, more frequently than in
nIBCs. Our results show some overlap with these results (Table S3).
We here identified four 17q21 genes, NSF, ARL17P1, ARL17 and
KIAA1267 targeted by loss in 17% of IBCs (Table S3).
In both IBCs and nIBCs the number of regions with CNAs was
very close and many altered regions were similar, suggesting that
common genes are involved in both types. However, some
common regions displayed higher frequency and/or higher
amplitude of alteration in IBCs, and other regions were specifically
altered in IBCs such as 5p15.33, previously associated with poor
prognosis in breast [61] and bladder cancers [62].
Figure 3. Discriminative power of the 24-gene signature and prognostic value in nIBCs. A) Classification of the 173 breast cancers (124
nIBCs and 49 IBCs) from which we have generated the 24-gene IBC signature (learning set) by leave-one-out cross-validation. Samples are ordered
from left to right according to the decreasing prediction score defined by the 24-gene model. The vertical dashed line indicates the threshold 0 that
separates the ‘‘IBC-like class’’ (left of the line) and the ‘‘nIBC-like class’’ (right to the line). Below the curve are some histoclinical and molecular features
of the samples: from top to bottom, clinical type (green for nIBC, and orange for IBC), SBR grade (white for grade I, grey for II, and black for III), IHC ER,
ERBB2, and P53 status (white for negative, and black for positive). The p-value of correlations between the two tumor classes (‘‘IBC-like’’ and ‘‘nIBC-
like) and these features is indicated as follows: ***, ,0.001; **, ,0.01; *, ,0.05; N, ,0.1; NS, not significant. B) The classification is validated in the set of
24 independent samples (10 nIBCs and 14 IBCs). C) The same classification method is applied to 1,781 publicly available nIBCs, allowing defining two
classes: ‘‘IBC-like’’ and ‘‘nIBC-like’’. D) Kaplan-Meier DFS curves of the two nIBC classes defined in C.
doi:10.1371/journal.pone.0016950.g003
Table 4. Uni- and multivariate logistic regression analyses of
IBC/nIBC distinction, including the 24-gene signature.
Univariate Multivariate
N coef p** N coef p**
ER pos vs neg 197 20.5 0.11
ERBB2 pos vs neg 185 2.06 3.53E-08 153 2.44 5.34E-05
P53 pos vs neg 163 1.28 6.08E-04 153 0.42 0.45
Grade 2–3 vs 1 190 18.02 0.99
nIBC-like vs IBC-like 197 23.23 2.29E-15 153 23.05 3.12E-08
*Logistic regression analysis using the glm function in R’s statistical package.
**Significance was estimated by specifying a binomial family for model with a
logit link.
doi:10.1371/journal.pone.0016950.t004
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similarly altered in IBCs and nIBCs in terms of frequency and
amplitude of aberrations. However, a larger number of genes
displayed recurrent amplifications in IBCs than in nIBCs. Some
genes, such as CCND1 and FGFR1, were amplified at the same
frequency in the two types, whereas others (99 out of 321
recurrently amplified, 31%), such as ERBB2 and MYC, were more
often amplified in IBCs. Of note, all high-level CNAs differentially
represented between the two types were associated with IBCs, and
none with nIBCs. Several of them code for validated or potential
therapeutic targets, which could contribute to enlarge our
therapeutic armament in IBC. The difference between IBCs and
nIBCs was much less important regarding the genes recurrently
deleted. The deletion of the RB1 tumor suppressor gene likely
contributes to the genomic instability in IBC.
IBC and transcriptional deregulation
Whole-genome gene expression profiling did not distinguish
IBCs and nIBCs more than did aCGH. To our knowledge, the
information about the relationship between gene CNAs and
mRNA expression in IBC is scarce in the literature. In the present
study, we restricted the analysis of expression data to genes with
DNA CNA. Having identified the genes with a CNA in at least
two IBCs and in at least two nIBCs, we determined those whose
mRNA expression correlated with the CNA. In both tumor types,
,10% of gained genes presented such correlation, in agreement
with previous observations obtained with low resolution tech-
niques and less samples in nIBC series [34,63]. In contrast, this
percentage for the genes with loss/deletion was smaller in IBCs
(1.4%) than in nIBCs (9.5%), suggesting that epigenetic mecha-
nisms might be more operational in IBCs than in nIBCs.
IBC candidate genes
Integrated analysis of aCGH and expression data identified 24
genes as potential IBC-specific candidate oncogenes, whereas no
IBC-specific gene inactivated by loss was found. This does not rule
out the likely existence of IBC-specific tumor suppressor genes
inactivated by other mechanisms, as well as the existence of a gene
expression signatures identified by the sole comparison of whole-
genome expression data of IBC vs nIBC. Importantly, the
discriminative power of the predictive model - built from the
expression levels of these 24 genes - was validated in an
independent sample set. Furthermore, this model was an
independent prognostic feature in a multicentric series of 1781
nIBCs, indirectly validating its association with IBC, known to be
more aggressive than nIBC.
Whether these genes are causative or even predictive of the IBC
phenotype in a biological sense or reflect aggressiveness or another
associated phenomenon remain to be explored by further in-depth
experimental analyses. Several encode proteins involved in the
protein translation and transport: MRPL27, a component of
mitochondrial ribosomes; VPS13B, involved in vesicle-mediated
sorting and transport of proteins within the cell; ABCC3, an ATP-
binding cassette transporter, and PABPC1 [64]. Increasing
evidence points to a crucial role of translational regulation in
cancer development and progression, notably in IBC [65].
PABPC1 is a poly(A)-binding protein (PABP) required for
translation initiation. Its interaction with the translation initiation
factor eIF4G is crucial for the translational stimulatory effect
conferred by the poly(A) tail. In IBC, eIF4G1 reprograms the
protein synthetic machinery for specifically increasing the
translation of certain mRNAs, notably that encoding p120
catenin, resulting in an increased stabilization of E-cadherin,
and that encoding VEGF [66, Silvera, 2009 #2199]]. E-cadherin
stabilization maintains the structure of tumor emboli, allowing
them to survive and to metastasize as entire structures. VEGF
expression accounts for high levels of angiogenesis in IBC and
resistance to hypoxia. Our result suggests that PABPC1 could also
participate and potentiates this process, allowing IBC cells to adapt
to the persistent hypoxia they experience as tumor emboli. Other
genes are associated with cell cycle progression: RBM13/MAK16
[67], TAF2, ATAD2, UTP23, MTBP, and DSCC1. TAF2 is a
general transcription factor particularly involved in the G2/M
transition [68]. ATAD2, as target of E2F, ER and coactivator of
MYC [69], links the 3 corresponding pathways, and likely
contributes to the aggressiveness of disease through the enhance-
ment of MYC-dependent transcription [70]. UTP23 [71] is a
component of the small subunit processome, required for ribosome
biogenesis and cell cycle progression at G1. MTBP regulates the
Table 5. Cox univariate and multivariate analyses of DFS in the public series of nIBCs.
Univariate Analysis Multivariate analysis
N HR [95%CI] p N HR [95%CI] p
Age, 1372 0.917 [0.76–1.11] 0.37
.50y vs #50y
Pathological axillary lymph node status, 1627 1.33 [1.12–1.58] 0.0013 1235 1.25 [1.01–1.54] 3.90E-02
pos vs neg
Pathological tumor size, 1352 2.08 [1.69–2.56] 3.00E-12 1235 1.71 [1.37–2.15] 3.00E-06
pT2-4 vs pT1
Grade, 1291 2.57 [1.87–3.54] 7.80E-09 1235 1.88 [1.33–2.65] 3.60E-04
2–3 vs 1
IHC ER status, 1638 0.571 [0.47–0.69] 3.40E-09 1235 0.56 [0.45–0.7] 3.00E-07
pos vs neg
IHC PR status, 453 0.73 [0.49–1.09] 0.12
pos vs neg
IBC-like vs nIBC-like 1661 1.42 [1.17–1.73] 0.00047 1235 1.34 [1.06–1.7] 1.50E-02
doi:10.1371/journal.pone.0016950.t005
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of p53 function [72]. DSCC1 is a component of an alternative
replication factor C complex that loads PCNA onto DNA during S
phase. Genes of the signature encode proteins involved in RNA
processing and transcription: the TAF2 and ATAD2 transcrip-
tional regulators, ARID2, which facilitates ligand-dependent
transcriptional activation by nuclear receptors [73], UTP23;
INTS2 and INTS8, subunits of the integrator complex, which
associates with RNA polymerase II and mediates 3-prime end
processing of snRNAs (Baillat, D, Cell 2005). Other genes are
associated with metabolism. ST3GAL1 encodes a glycosyltransfer-
ase that induces aberrant glycosylation of MUC1 in breast cancer
[4,74]. SQLE encodes a key enzyme of cholesterol biosynthesis,
whose expression is associated with poor survival in nIBCs [75].
Two genes, RAD21 and RAD54B, are associated with DNA repair
[76]. Finally, four genes (PTPN2, MTSS1, EPN3, and C17ORF37)
are associated with cell migration and adhesion and/or poor
prognosis of breast cancer. The PTPN2/TC-PTP phosphatase
stimulates the ERK pathway [77], and its decreased expression
markedly impairs IGF2 induced MCF7 migration [78]. The
presence of MTSS1, which encodes for metastasis suppressor 1
[79] appears paradoxal, given its favorable prognostic impact in
breast cancer [80]. However, it has been suggested that MTSS1 is
unlikely to be a metastasis suppressor, but interacted with RAC,
actin and actin-associated proteins to modulate lamellipodia
formation [81]. Epsin 3 (EPN3) is involved in extracellular
matrix-epithelial cells interactions [82]. C17orf37, whose expres-
sion correlates with grade and stage of nIBC [83], promotes
invasion and migration of prostate cancer cells by enhancing
secretion of uPA, MMP9 and VEGF through NF-kB pathway
[84]. Altogether, these different processes (protein translation and
transport, cell cycle, RNA processing and transcription, metabo-
lism, cell migration) are consistent with the hyperproliferative and
invasive phenotype of IBC. Some of them (protein processing,
RNA translation, proliferation and lipid metabolism) have been
previously reported as overrepresented among genes or pathways
associated with IBC [29,31].
In conclusion, we report the first description of genomic profiles
of IBCs, on a large sample size and with a high-resolution aCGH
platform, and the first integrated genomic analysis comparing IBC
vs nIBC. Thisrepertoire of whole-genome CNAs in IBCs may serve
of basis for further investigations. We show the genomic complexity
and heterogeneity of IBCs, which globally look like nIBCs. Many
genes targeted by CNA - some of them specific of IBC - have not
been previously reported in breast cancer. We have identified 24
IBC-specific potential oncogenes that could explain, at least
partially, the IBC phenotype and its aggressiveness, and lead to
the development of new therapeutic strategies. As such, they
represent new candidates for further clinical and functional
validation in IBC. One of them, PABPC1, is particularly interesting
as it likely potentiates the role of an alteration recently discovered as
essential in IBC pathogenesis. Our findings, as well as the
comprehensive database of CNA and mRNA expression generated,
constitute a novel step towards the goal of better understanding, and
perhaps treating, IBC, even if other alterations of the tumor, as well
as those of its microenvironment, at other molecular levels such as
DNA mutations, epigenetic regulations, microRNAs [85], proteins
and others [4,25] still need to be identified.
Supporting Information
Figure S1 Integrated comparative analysis of IBcs and nIBCs
with the three successive steps numbered 1, 2 and 3).
(PPT)
Figure S2 Whole-genome expression profiling of IBCs and
nIBCs. A) Hierarchical clustering of 197 samples and 12,813 probe
sets with significant variation in mRNA expression level across the
samples. Each row of the data matrix represents a gene and each
column represents a sample. Expression levels are depicted
according to the color scale shown at the bottom. Red and green
indicate expression levels respectively above and below the median.
The magnitude of deviation from the median is represented by the
color saturation. The dendrogram of samples (above matrixes)
represents overall similarities in gene expression profiles and is
zoomed in B. Colored bars to the right indicate the locations of 6
gene clusters of interest (ECM means extra-cellular matrix). B)
Dendrograms of samples. Top, three large groups of tumor samples
(designated I to III) are evidenced and delimited by orange vertical
lines. Below the dendrogram, are some histoclinical and molecular
features of the samples: from top to bottom, clinical type (green for
nIBC, and orange for IBC), SBR grade (white for grade I, grey for
II, and black for III), IHC ER, ERBB2, and P53 status (white for
negative, and black for positive), and intrinsic molecular subtypes
(dark blue for luminal A, light blue for luminal B, red for basal, pink
for ERBB2-overexpressing, and green for normal-like).
(PPT)
Figure S3 Proportion of genomic patterns in IBCs and nIBCs.
(PPT)
Figure S4 6q21 gains are more frequent in IBCs than nIBCs.
Profiles of chromosome 6 show higher 6q21 gain frequency in IBC
tumors than in nIBC (A). Regional genomic profiles were established
with CGH analyticsH software (Agilent Technologies), for IBC and
nIBC cases (panels B and C) both within the genomic interval [105.9–
114.7 Mb] of the long arm of the chromosome 6 (hg17 human
genome mapping; build 35 from NCBI). Profiles are distinguishable by
different colors corresponding to different cases. Several IBC cases
showed 6q21 gain or regional or focused amplification (B), whereas
only two nIBC cases displayed a regional amplification (C).
(PPT)
Table S1 Description of the public nIBC data sets.
(XLS)
Table S2 Histoclinical correlations of the three aCGH-clustered
groups.
(XLS)
Table S3 Regions with CNAs in IBCs.
(XLS)
Table S4 Genes with high level CNAs in IBCs and/or nIBCs.
(XLS)
Table S5 Regions with CNAs in nIBCs.
(XLS)
Table S6 Genes with copy number gain/amplification frequen-
cies significantly different between IBCs and nIBCs.
(XLS)
Table S7 Genes with copy number loss/deletion frequencies
significantly different between IBCs and nIBCs.
(XLS)
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(XLS)
Table S9 List of 24 genes with gain or amplification correlated
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